Hemogenyx Pharmaceuticals Balance Sheet

Financials in millions GBP. Fiscal year is January - December.

Millions GBP. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	1.59	0.16	1.25	2.53	6.84
Cash & Short-Term Investments	1.59	0.16	1.25	2.53	6.84
Cash Growth	896.10%	-87.23%	-50.74%	-62.98%	277.48%
Other Receivables	0.01	0.01	0.01	0.01	0.01
Receivables	0.01	0.01	0.01	0.01	0.01
Prepaid Expenses	0.44	0.67	0.92	0.05	0.29
Total Current Assets	2.03	0.84	2.17	2.59	7.14
Property, Plant & Equipment	1.8	2.73	3.31	3.92	0.8
Other Intangible Assets	0.18	0.48	0.47	0.44	0.44
Other Long-Term Assets	0.16	0.17	0.15	0.14	0.14
Total Assets	4.18	4.21	6.11	7.09	8.52
Accounts Payable	0.97	0.68	0.3	0.37	0.3
Accrued Expenses	0.06	0.05	0.08	0.05	0.05
Current Portion of Leases	0.44	0.42	0.36	0.32	0.01
Total Current Liabilities	1.47	1.16	0.74	0.75	0.35
Long-Term Leases	1.56	2.2	2.58	3.1	-
Total Liabilities	3.03	3.36	3.32	3.85	0.35
Common Stock	0.06	0.04	11.76	9.8	9.8
Additional Paid-In Capital	29.24	21.39	19.94	16.81	16.81
Retained Earnings	-38.75	-29.42	-23.8	-17.11	-13.13
Comprehensive Income & Other	10.65	8.9	-5.07	-6.22	-5.28
Total Common Equity	1.2	0.9	2.82	3.28	8.19
Minority Interest	-0.05	-0.04	-0.04	-0.03	-0.02
Shareholders' Equity	1.14	0.85	2.78	3.24	8.17
Total Liabilities & Equity	4.18	4.21	6.11	7.09	8.52
Total Debt	2	2.62	2.95	3.42	0.01
Net Cash (Debt)	-0.42	-2.46	-1.7	-0.89	6.83
Net Cash Growth	-	-	-	-	3609.03%
Net Cash Per Share	-0.09	-0.75	-0.60	-0.36	3.53
Filing Date Shares Outstanding	6.04	3.5	3.35	2.85	2.45
Total Common Shares Outstanding	6.04	3.5	2.94	2.45	2.45
Working Capital	0.56	-0.32	1.43	1.85	6.79
Book Value Per Share	0.20	0.26	0.96	1.34	3.34
Tangible Book Value	1.01	0.42	2.35	2.83	7.75
Tangible Book Value Per Share	0.17	0.12	0.80	1.16	3.16
Machinery	0.04	0.05	0.04	0.03	0.02
Leasehold Improvements	0.64	0.7	0.69	0.72	0.64